Recent advances in preclinical drug development in multiple sclerosis

Bibliography

• RUDICK RA, COHEN JA, WEINSTOCK-GUTTMAN B et al: Management of multiple sclerosis. New Engl. J. Med. (1997) 337(22):1604–1611.
   PubMed Web of Science ®Google Scholar
• MARTIN R: Immunological aspects of experimental al-lergic encephalomyelitis and multiple sclerosis and their application for new therapeutic strategies. J. Neu-ral Trans. Suppl. (1997) 49:53–67.
   PubMedGoogle Scholar
• ZIPP F, SOMMER N, ROSENER M, DICHGANS J, MARTIN R: Multiple sclerosis. New therapeutic strategies in the experimental stage. Nervenarzt (1997) 68(2):94–101.
   Google Scholar
• RODRIGUEZ M: Multiple sclerosis: insights into mo-lecular pathogenesis and therapy. Mayo. Clin. Proc. (1997) 72(7):663–664.
   PubMed Web of Science ®Google Scholar
• HOHLFELD R: Biotechnological agents for the immuno-therapy of multiple sclerosis. Principles, problems and perspectives. Brain (1997) 120 (Pt 5):865–916.
   Google Scholar
• ••Comprehensive and timely review of basic science and drugdevelopment in MS focused on immune system biology.
   Google Scholar
• SADOVNICK AD, EBERS GC, DYMENT DA, RISCH NJ: Evi-dence for genetic basis of multiple sclerosis. The Cana-dian Collaborative Study Group. Lancet (1996) 347 (9017):1728–1730.
   PubMed Web of Science ®Google Scholar
• Handbook of Multiple Sclerosis. (Second Edition). Stuart D Cook, WC Koller (Eds.), Marcel Dekker, Inc., Monticello, NY (1996).
   Google Scholar
• Frontiers in Multiple Sclerosis: Clinical Research and Ther-apy 0 Abramsky, Haim (Eds.), Mosby, London, UK (1997).
   Google Scholar
• Multiple Sclerosis: Clinical and Pathogenetic Basis. Cedric S Raine (Ed.), Chapman and Hall, London, UK (1997).
   Google Scholar
• Multiple Sclerosis. GC Ebers (Ed.), FA Davis Company, Phila-delphia, PA (1998).
   Google Scholar
• HILLERT J: Handbook of Multiple Sclerosis. (Second Edi-tion). SD Cook (Ed.), Marcel Dekker, Inc., Monticello, NY (1996):19–51.
   Google Scholar
• BROCKE S, HAUSMANN S, STEINMAN L, WUCHERPFEN-NIG KW: Microbial peptides and superantigens in the pathogenesis of autoimmune diseases of the central nervous system. Semin. Immunol. (1998) 10(1):57–67.
   PubMed Web of Science ®Google Scholar
• MERELLI E, BEDIN R, SOLA P et al: Human herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis patients, normal adults and chil-dren. J. Neurol. (1997) 244(7):450–454.
   PubMed Web of Science ®Google Scholar
• TOURTELLOTTE VJSAWW: Herpes viruses in active plaques of postmortem multiple sclerosis brain tissue. In: Frontiers in Multiple Sclerosis: Clinical Research and Therapy 00 Abramsky, Haim (Eds.), Mosby, London, UK (1997) :129–135.
   Google Scholar
• CASERTA MT, HALL CB, SCHNABEL K et al.: Neuroinva-sion and persistence of human herpesvirus 6 in chil-dren. J. Infect. Dis. (1994) 170(6):1586–1589.
   PubMed Web of Science ®Google Scholar
• CHALLONER PB, SMITH KT, PARKER JD et al.: Plaque-associated expression of human herpesvirus 6 in mul-tiple sclerosis. Proc. Natl. Acad. Sci. USA (1995) 92(16)7440–7444.
   Google Scholar
• •Using molecular and immunohistochemical analysis, this paper reveals the association of a pattern of viral infection of HHV-6 variant B group 2 and nuclear staining of oligoden-drocytes in MS.
   Google Scholar
• SOLDAN SS, BERTI R, SALEM N et al. Association of hu- man herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and de-tection of serum HHV-6 DNA [see comments]. Nature Med. (1997) 3(12):1394–1397.
   PubMed Web of Science ®Google Scholar
• FREDRIKSON S, SODERSTROM M, HILLERT J, SUN JB, KALL TB, LINK H: Multiple sclerosis: occurrence of mye-lin basic protein peptide-reactive T cells in healthy family members. Acta Neurol Scand. (1994) 89(3):184–189.
   PubMed Web of Science ®Google Scholar
• SUN JB, OLSSON T, WANG WZ et al. Autoreactive T and B cells responding to myelin proteolipid protein in mul-tiple sclerosis and controls. Eur. j Immunol. (1991) 21(6):1461–1468
   PubMed Web of Science ®Google Scholar
• OLSSON T, SUN J, HILLERT J et al. Increased numbers of T cells recognising multiple myelin basic protein epi-topes in multiple sclerosis. Eur. j Immunol. (1992) 22 (4) 1083–1087
   PubMed Web of Science ®Google Scholar
• GROSSMAN RI, GOMORI JM, RAMER KN, LEXA FJ, SCHNALL MD: Magnetisation transfer: theory and clini-cal applications in neuroradiology. Radiographics (1994) 14(2):279–290.
   PubMed Web of Science ®Google Scholar
• MILLER DH, GROSSMAN RI, REINGOLD SC, MCFARLANDHF: The role of magnetic resonance techniques in un-derstanding and managing multiple sclerosis. Brain (1998) 121:3–24.
   PubMed Web of Science ®Google Scholar
• FILIPPI M, YOUSRY T, ROCCA MA, FESL G, VOLTZ R, COMIG: Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis. Acta. Neurol. Scand. (1997) 95 (6):331–334.
   PubMed Web of Science ®Google Scholar
• LYCKLAMA A, NIJEHOLT GJ, BARKHOF F et al.: MR of thespinal cord in multiple sclerosis: relation to clinical subtype and disability. Am. J. Neuroradiol. (1997) 18 (6) :1041–1048.
   PubMed Web of Science ®Google Scholar
• TRUYEN L, VAN WAESBERGHE JH, VAN WALDERVEEN MA et al. Accumulation of hypointense lesions (black holes') on Ti spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology (1996) 47(6) 1469–1476
   Google Scholar
• GIUGNI E, POZZILLI C, BASTIANELLO S et al. MRI meas- ures and their relations with clinical disability in relapsing-remitting and secondary progressive multi- ple sclerosis. Multiple Sclerosis (1997) 3 (4) :221–225.
   PubMedGoogle Scholar
• LOSSEFF NA, WANG L, LAI HM et al.: Progressive cere-bral atrophy in multiple sclerosis. A serial MRI study. Brain (1996) 119 (Pt 6):2009–2019.
   Google Scholar
• LOSSEFF NA, WEBB SL, ORIORDAN JI et al.: Spinal cord atrophy and disability in multiple sclerosis. A new re-producible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 119\(Pt 3)701–708.
   Google Scholar
• KIMURA H, GROSSMAN RI, LENKINSKI RE, GONZALEZ-SCARANO F: Proton MR spectroscopy and magnetiza-tion transfer ratio in multiple sclerosis: correlative findings of active versus irreversible plaque disease. Am. J. Neuroradiol. (1996) 17(8):1539–1547.
   PubMed Web of Science ®Google Scholar
• DAVIE CA, BARKER GJ, THOMPSON AJ, TOFTS PS, MCDONALD WI, MILLER DH: 111 magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclero-sis. J. Neurol Neurosurg. Psychiat. (1997) 63(6):736–742.
   PubMed Web of Science ®Google Scholar
• SWANBORG RH: Experimental autoimmune encepha-lomyelitis in rodents as a model for human demyeli-nating disease. Clin. Immunol. Immunopathol. (1995) 77(1):4–13.
   PubMedGoogle Scholar
• WEKERLE H, KOJIMA K, LANNES-VIEIRA J, LASSMANN H, LININGTON C: Animal models. Ann. Neurol (1994) 36(Suppl.):S47–53.
   Google Scholar
• GENAIN CP, HAUSER SL: Creation of a model for multi-ple sclerosis in Callithrix jacchus marmosets. J. Mol. Med. (1997) 75(3):187–197.
   PubMed Web of Science ®Google Scholar
• •The authors describe a new EAE model in a nonhuman pri-mate, the common marmoset Callithrixjacchus.
   Google Scholar
• PRIBYL TM, CAMPAGNONI CW, KAMPF K et al.: The hu-man myelin basic protein gene is included within a 179-kilobase transcription unit: expression in the im-mune and central nervous systems. Proc. Natl. Acad. ScL USA (1993) 90(22):10695–10699.
   PubMed Web of Science ®Google Scholar
• FRITZ RB, ZHAO ML: Thymic expression of myelin ba-sic protein (MBP). Activation of MBP- specific T cells by thymic cells in the absence of exogenous MBP. J. Immu-nol. (1996) 157(12):5249–5253.
   Google Scholar
• •This paper offers evidence for the presence of naturally oc-curring MBP exon 2-T-cells isolated from the thymus of healthy SJL mice which induced EAE after adoptive transfer of activated cells.
   Google Scholar
• MACKENZIE-GRAHAM AJ, PRIBYL TM, KIM S et al.: Myelin protein expression is increased in lymph nodes of mice with relapsing experimental autoimmune en-cephalomyelitis. J. Immunol. (1997) 159 (9) :4602–4610.
   PubMed Web of Science ®Google Scholar
• ••Golli-MBP expression is shown to be increased by two tofive fold in macrophages during chronic EAE. This paper provides evidence for the expression of myelin proteins out-side of the nervous system and BBB during disease and po-tential role in autoantigen expression or epitope spreading.
   Google Scholar
• TIENARI PJ, KUOKKANEN S, PASTINEN T etal.: Golli-MBP gene in multiple sclerosis susceptibility. J. Neuroimmu-nol. (1998) 81(1–2):158–167.
   Google Scholar
• ••These authors describe a genetic analysis for mutations inthe Golli-MBP locus in 151 MS families and an association between the existence of a tetranucleotide repeat and the occurence of MS.
   Google Scholar
• CRITCHFIELD JM, RACKE MK, ZUNIGA-PFLUCKER JC et T cell deletion in high antigen dose therapy of auto-immune encephalomyelitis. Science (1994) 263(51501139–1143.
   Web of Science ®Google Scholar
• PAPE KA, MERICA R, MONDINO A, KHORUTS A, JENKINS MK: Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance. J. Immunol. (1998) 160(104719–4729.
   Web of Science ®Google Scholar
• MONDINO A, KHORUTS A, JENKINS MK: The anatomy of T-cell activation and tolerance. Proc. Natl. Acad. Sci. USA (1996) 93(6):2245–2252.
   PubMed Web of Science ®Google Scholar
• WHITACRE CC, GIENAPP IE, OROSZ CG, BITAR DM: Oraltolerance in experimental autoimmune encephalo-myelitis. III. Evidence for clonal anergy. J. Immunol (1991) 147(7):2155–2163.
   Google Scholar
• •One of the first reports of the phenomena of immune toler-ance induced by oral administration of MBP and mechanism of action.
   Google Scholar
• BAI XF, SHI FD, XIAO BG et al.: Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activat-ing regulatory cells expressing IL-4 and TGF-beta mRNA. J. Neuroimmunol. (1997) 80 (1-2) :65–75.
   PubMed Web of Science ®Google Scholar
• KENNEDY KJ, SMITH WS, MILLER SD, KARPUS WJ: Induc-tion of antigen-specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis: a comparison between oral and peripheral tolerance. J. Immunol. (1997) 159(2):1036–1044.
   PubMed Web of Science ®Google Scholar
• WEINER HL: Oral tolerance for the treatment of autoim-mune diseases. Ann. Rev. Med. (1997) 48:341–351.
   PubMed Web of Science ®Google Scholar
• FUKAURA H, KENT SC, PIETRUSEWICZ MJ, KHOURY SJ, WEINER HL, HAFLER DA: Antigen-specific TGF-betal se-cretion with bovine myelin oral tolerization in multi-ple sclerosis. Ann. NY Acad. ScL (1996) 778:251–257.
   PubMed Web of Science ®Google Scholar
• LAFAILLE JJ, KEERE FV, HSU AL et al.: Myelin basic protein-specific T helper 2 (Th2) cells cause experi-mental autoimmune encephalomyelitis in immunode-ficient hosts rather than protect them from the disease. J. Exp. Med. (1997) 186(2):307–312.
   PubMed Web of Science ®Google Scholar
• •This paper provides evidence that Th2 cells are potentially capable of inducing EAE, challenging assumptions that Thl cells only induce disease or Th2 cells are inherently protec-tive. Resistance to developing EAE induced by Th2 cells re-quires the presence of a counter-regulatory network.
   Google Scholar
• LEDERER JA, PEREZ VL, DESROCHES L, KIM SM, ABBAS AK, LICHTMAN AH: Cytokine transcriptional events during helper T cell subset differentiation. J. Exp. Med. (1996) 184(2)397–406.
   Google Scholar
• ••This paper describes the molecular mechanisms and tran-scriptional events responsible for the differentiation of T-cells into Thl and Th2 phenotypes.
   Google Scholar
• CANNELLA B, GAO YL, BROSNAN C, RAINE CS: IL-10 fails to abrogate experimental autoimmune encephalo-myelitis. J. NeuroscL Res. (1996) 45 (6):735–746.
   PubMed Web of Science ®Google Scholar
• NAGELKERKEN L, BLAUW B, TIELEMANS M: IL-4 abro-gates the inhibitory effect of IL-10 on the development of experimental allergic encephalomyelitis in SJL mice. Int. Immunol. (1997) 9(9) :1243–1251.
   PubMed Web of Science ®Google Scholar
• SHAW MK, LORENS JB, DHAWAN A et al: Local deliveryof interleukin 4 by retrovirus-transduced T lympho-cytes ameliorates experimental autoimmune en-cephalomyelitis. J. Exp. Med. (1997) 185 (9) :1711–1714.
   PubMed Web of Science ®Google Scholar
• LEHMANN D, KARUSSIS DM, FLURESCO D eta].: Immuno-modulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J. Neuroimmunol. (1997) 74(1–2):102–110.
   Google Scholar
• LEHMANN D, KARUSSIS D, MIZRACHI-KOLL R, LINDE AS,ABRAMSKY 0: Inhibition of the progression of multi-ple sclerosis by linomide is associated with upregula-tion of CD4±/CD45RA+ cells and downregulation of CD4/CD45R0+ cells. Clin. Immunol. Immunopathol. (1997) 85(2):202–209.
   PubMedGoogle Scholar
• KARUSSIS DM, MEINER Z, LEHMANN D et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology (1996) 47(2) 341–346
   PubMed Web of Science ®Google Scholar
• GREWAL IS, FOELLMER HG, GREWAL KD et al. Require- ment for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalo-myelitis. Science (1996) 273 (5283) 1864–1867
   PubMed Web of Science ®Google Scholar
• SAMOILOVA EB, HORTON JL, ZHANG H, CHEN Y: CD40Lblockade prevents autoimmune encephalomyelitis and hampers Till but not TH2 pathway of T cell differ-entiation. J. Mol. Med. (1997) 75(8):603–608.
   PubMedGoogle Scholar
• NICHOLSON LB, MURTAZA A, HAFLER BP, SETTE A, KUCHROO VK: AT cell receptor antagonist peptide in-duces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc. Natl. Acad. Sci. USA (1997) 94(17):9279–9284.
   PubMed Web of Science ®Google Scholar
• GOLD DP, SMITH RA, GOLDING AB et al.: Results of aPhase I clinical trial of a T-cell receptor vaccine in pa-tients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide. J. Neuroimmunol. (1997) 76(1–2):29–38.
   Google Scholar
• MCCUTCHEON M, WEHNER N, WENSKY A et al.: A sensi-tive ELISPOT assay to detect low-frequency human T lymphocytes. J. Immunol. Methods (1997) 210(2) :149–166.
   PubMed Web of Science ®Google Scholar
• GAUR A, BOEHME SA, CHALMERS D et al.: Ameliorationof relapsing experimental autoimmune encephalo-myelitis with altered myelin basic protein peptides in-volves different cellular mechanisms. J. Neuroimmunol. (1997) 74(1-2):149–158.
   PubMed Web of Science ®Google Scholar
• ARNON R, SELA M, TEITELBAUM D: New insights into themechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J. Neurol (1996) 243(4 Suppl. 1):S8–13.
   Google Scholar
• FRIDKIS-HARELI M, STROMINGER JL: Promiscuous bind-ing of synthetic copolymer 1 to purified HLA-DR mole-cules. J. Immunol. (1998) 160(9):4386–4397.
   PubMed Web of Science ®Google Scholar
• BEN-NUN A, MENDEL I, BAKIMER R et al: The autoim-mune reactivity to myelin oligodendrocyte glycopro-tein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J. Neurol. (1996) 243(4 Suppl. 0:514–22.
   Google Scholar
• MCRAE BL, VANDERLUGT CL, DAL CANTO MC, MILLERSD: Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune en-cephalomyelitis. J. Exp. Med. (1995) 182 (1) :75–85.
   PubMed Web of Science ®Google Scholar
• •Data presented from the EAE model support the theory of intramolecular epitope spreading for a secondary encepha-logenic epitopes of PLP.
   Google Scholar
• TUOHY VK, YU M, WEINSTOCK-GUTTMAN B, KINKEL RP: Diversity and plasticity of self recognition during the development of multiple sclerosis. J. Clin. Invest. (1997) 99 (7):1682–1690.
   PubMed Web of Science ®Google Scholar
• •This study looks at the reactivity to diverse PLP epitopes over time, providing an approach to examine epitope spreading in MS.
   Google Scholar
• YU M, JOHNSON JM, TUOHY VK: A predictable sequen-tial determinant spreading cascade invariably accom-panies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific ther-apy after onset of clinical disease. J. Exp. Med. (1996) 183 (4) :1777–1788.
   PubMed Web of Science ®Google Scholar
• VANDERLUGT CL, KARANDIKAR NJ, LENSCHOW DJ, DALCANTO MC, BLUESTONE JA, MILLER SD: Treatment with intact anti-B7-1 mAb during disease remission en-hances epitope spreading and exacerbates relapses in R-EAE. J. Neuroimmunol. (1997) 79(2) :113–118.
   PubMed Web of Science ®Google Scholar
• BACHMANN MF, MCKALL-FAIENZA K, SCHMITS R et al.:Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity (1997) 7(4):549–557.
   PubMed Web of Science ®Google Scholar
• SOILU-HANNINEN M, ROYTTA M, SALMI A, SALONEN R:Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. J. Neuroim-munol. (1997) 72(0:95–105.
   PubMedGoogle Scholar
• LEGER 0J, YEDNOCK TA, TANNER L et al.: Humanizationof a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Human Antibodies (1997) 8 (1) 3–16.
   Google Scholar
• SELMAJ K, RAINE CS, CANNELLA B, BROSNAN CF: Identi-fication of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. (1991) 87(3)949–954.
   Google Scholar
• VORA AJ, KIDD D, MILLER DH et al.: Lymphocyte-endothelial cell interactions in multiple sclerosis: dis-ease specificity and relationship to circulating tumour necrosis factor-alpha and soluble adhesion molecules. Multiple Sclerosis (1997) 3 (3) :171–179.
   PubMed Web of Science ®Google Scholar
• GRAY P, AGGARWAL B, BENTON C, BRINGMAN T, HEN-ZEL W: Cloning and expression of the cDNA for human 852 Recent advances in preclinical drug development in multiple sclerosis lymphotoxin: a lymphokine with tumor necrosis ac-tivity. Nature (1984) 312:721–724.
   PubMed Web of Science ®Google Scholar
• TSUKAMOTO T, ISHIKAWA M, YAMAMOTO T: Suppres-sive effects of TNF-alpha on myelin formation in vitro. Acta. Neurol. Scand. (1995) 91(0:71–75.
   PubMedGoogle Scholar
• RAINE CS: The Norton Lecture: a review of the oli-godendrocyte in the multiple sclerosis lesion. J. Neuro-immunol. (1997) 77(2):135–152.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of the neuropathology in MS.
   Google Scholar
• KORNER H, RIMINTON DS, STRICKLAND DH, LEMCKERT FA, POLLARD JD, SEDGWICK JD: Critical points of tumor necrosis factor action in central nervous system auto-immune inflammation defined by gene targeting. J. Exp. Merl. (1997) 186(9):1585–15890.
   PubMed Web of Science ®Google Scholar
• LIU J, MARINO MW, WONG G et al.: TNF is a potent anti-inflammatory cytokine in autoimmune-mediated de-myelination. Nature Merl. (1998) 4 (1) :78–83.
   PubMed Web of Science ®Google Scholar
• TAUPIN V, RENNO T, BOURBONNIERE L, PETERSON AC,RODRIGUEZ M, OWENS T: Increased severity of experi-mental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system. Eur. J. Immunol. (1997) 27(4):905–913.
   PubMed Web of Science ®Google Scholar
• WANG CY, MAYO MW, BALDWIN AS, JR.: TNF- and can-cer therapy-induced apoptosis: potentiation by inhibi-tion of NF-kappaB. Science (1996) 274(5288):784–787.
   Google Scholar
• KLINKERT WE, KOJIMA K, LESSLAUER W, RINNER W, LASSMANN H, WEKERLE H: TNF-alpha receptor fusion protein prevents experimental auto-immune en-cephalomyelitis and demyelination in Lewis rats: an overview. J. Neuroimmunol (1997) 72(2):163–168.
   PubMed Web of Science ®Google Scholar
• KORNER H, LEMCKERT FA, CHAUDHRI G, ETTELDORF S,SEDGWICK JD: Tumor necrosis factor blockade in ac-tively induced experimental autoimmune encephalo-myelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur. J. Immunol. (1997) 27(8):1973–1981.
   PubMed Web of Science ®Google Scholar
• TCHELINGERIAN JL, MONGE M, LE SAUX F, ZALC B, JAC-QUE C: Differential oligodendroglial expression of the tumor necrosis factor receptors in vivo and in vitro. J. Neurochem. (1995) 65(5)2377–2380.
   Google Scholar
• RUDDLE NH, BERGMAN CM, MCGRATH KM etal. An anti- body to lymphotoxin and tumor necrosis factor pre-vents transfer of experimental allergic encephalomyelitis. J. Exp. Med. (1990) 172(4)1193–1200.
   Google Scholar
• SUEN WE, BERGMAN CM, HJELMSTROM P, RUDDLE NH: Acritical role for lymphotoxin in experimental allergic encephalomyelitis. J. Exp. Merl. (1997) 186(8):1233–1240.
   PubMed Web of Science ®Google Scholar
• MOLLER DR, WYSOCKA M, GREENLEE BM et al: Inhibi-tion of human interleukin-12 production by pentoxi-fylline. Immunology (1997) 91 (2):197–203.
   PubMed Web of Science ®Google Scholar
• MOLLER DR, WYSOCKA M, GREENLEE BM et al.: Inhibi-tion of IL-12 production by thalidomide. J. Immunol. (1997) 159(10):5157–5161.
   PubMed Web of Science ®Google Scholar
• BEAVO JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physic)]. Rev. (1995) 75:725–748.
   PubMed Web of Science ®Google Scholar
• DINTER H, ONUFFER J, FAULDS D, PEREZ HD: Phos-phodiesterase Type IV inhibitors in the treatment of multiple sclerosis. J. Mol Med. (1997) 75(2):95–102.
   PubMed Web of Science ®Google Scholar
• EIGLER A, SIEGMUND B, EMMERICH U, BAUMANN KH, HARTMANN G, ENDRES S: Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 syn-thesis and concurrent suppression of TNF production. Leukoc. Biol. (1998) 63(0:101–107.
   PubMedGoogle Scholar
• WILSON MS, BROWN N, HOUSLAY MD: Purification, characterisation and analysis of rolipram inhibition of a human Type WA cyclic AMP-specific phosphodies-terase expressed in yeast. Biochem. J. (1994) 304:407–415.
   PubMedGoogle Scholar
• SOMMER N, MARTIN R, MCFARLAND HF et al.: Therapeu-tic potential of phosphodiesterase Type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuro-immunol. (1997) 79(0:54–61.
   PubMedGoogle Scholar
• GENAIN CP, ROBERTS T, DAVIS RL et al.: Prevention of autoimmune demyelination in non-human primates by a cAMP- specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA (1995) 92 (8):3601–3605.
   PubMed Web of Science ®Google Scholar
• BARNETTE SB, ESSAYAN DM et al.: SB 207499 (Ariflo), a potent and selective second-generation phosphodies-terase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. (1998) 284(1):420–426.
   PubMed Web of Science ®Google Scholar
• RIECKMANN P, WEBER F, GUNTHER A et al.: Pentoxifyl-line, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J. Neuro-immunol. (1996) 64(2):193–200.
   PubMed Web of Science ®Google Scholar
• VAN OOSTEN BW, REP MH, VAN LIER RA et al.: A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in pa-tients with multiple sclerosis. J. Neuroimmunol. (1996) 66(1–2)49–55.
   Google Scholar
• KLEINMAN EF, CAMPBELL E, GIORDANO LA et al.: Strik-ing effect of hydroxamic acid substitution on the phos-phodiesterase Type 4 (PDE4) and TNEcc inhibitory activity of two series of rolipram analogues: implica-tions for a new active site model. J. Merl. Chem (1998) 41(3)266–270.
   Google Scholar
• UHM NP, LUKE YS, YONG VW: Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend pro-cesses along an astrocyte extracellular matrix. Glia (1998) 22:53–63.
   PubMed Web of Science ®Google Scholar
• CHANDLER S, MILLER KM, CLEMENTS JM et al.: Matrix metalloproteinases, tumor necrosis factor and multi-ple sclerosis: an overview. J. Neuroimmunol. (1997) 72(2):155–161.
   PubMed Web of Science ®Google Scholar
• KIESEIER BC, KIEFER R, CLEMENTS JM et al.: Matrix metalloproteinase-9 and -7 are regulated in experi-mental autoimmune encephalomyelitis. Brain (1998) 121(Pt 0:159–166.
   PubMedGoogle Scholar
• COSSINS JA, CLEMENTS JM, FORD J et al. Enhanced ex- pression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta. Neuropathol. (Berlin) (1997) 94 (6) :590–598.
   PubMed Web of Science ®Google Scholar
• CLEMENTS JA, WELLS GMA et al.: Matrix metalloprote-inase expression during experimental autoimmune encephaolomyelitis and effects of a combined matrix metalloptoteinase and tumour necorsis factor-a in-hibitor. J. Neuroimmunol. (1997) 74:85–94.
   PubMedGoogle Scholar
• MOSS MU, MILLA ME et al.: Cloning of a disintegrin met-alloproteinase that processes precursor tumour-necrosis factor-a. Nature (1997) 385:733–736.
   PubMed Web of Science ®Google Scholar
• •This paper describes the cloning and characterization of an enzyme that regulates specifically the proteolytic processing of TNFa.
   Google Scholar
• OKUDA Y, SAKODA S, FUJIMURA H, YANAGIHARA T: Ni-tric oxide via an inducible isoform of nitric oxide syn-thase is a possible factor to eliminate inflammatory cells from the central nervous system of mice with ex-perimental allergic encephalomyelitis. J. Neuroimmu-nol. (1997) 73(1-2):107–116.
   PubMed Web of Science ®Google Scholar
• BO L, DAWSON TM, WESSELINGH S et al. Induction of nitric oxide synthase in demyelinating regions of mul-tiple sclerosis brains. Ann. Neurol. (1994) 36(5) 778–786
   PubMed Web of Science ®Google Scholar
• CROSS AH, MANNING PT, STERN MK, MISKO TP: Evi-dence for the production of peroxynitrite in inflam-matory CNS demyelination. J. Neuroimmunol. (1997) 80:121–130.
   PubMed Web of Science ®Google Scholar
• HOOPER DC, SPITSIN S, KEAN RB et al.: Uric acid, a natu-ral scavenger of peroxynitrite, in experimental aller-gic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA (1998) 95(2):675–680.
   PubMed Web of Science ®Google Scholar
• MITROVIC B, IGNARRO LJ, MONTESTRUQUE S, SMOLL A, MERRILL JE: Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro. Neuroscience (1994) 61(3):575–585.
   PubMed Web of Science ®Google Scholar
• REDFORD EJ, KAPOOR R, SMITH KJ: Nitric oxide donors reversibly block axonal conduction: demyelinated ax-ons are especially susceptible. Brain (1997) 120(Pt 12) :2149–57.
   PubMedGoogle Scholar
• ••This paper demonstrates that axons demyelinated in vitroare susceptible to conduction block induced by nitric oxide. This paper suggests that nitric oxide may have direct effects on demyelinated axons and supports a new therapeutic goal for NOS inhibitors in MS.
   Google Scholar
• CROSS AH, MISKO TP, LIN RF, HICKEY WF, TROTTER JL, TILTON RG: Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental auto-immune encephalomyelitis in SJL mice. J. Clin. Invest. (1994) 93 (6) :2684–2690.
   PubMed Web of Science ®Google Scholar
• OKUDA Y, SAKODA S, FUJIMURA H, YANAGIHARA T: Aminoguanidine, a selective inhibitor of the inducible nitric oxide synthase, has different effects on experi-mental allergic encephalomyelitis in the induction and progression phase. J. Neuroimmunol. (1998) 81(1-2) :201–210.
   PubMed Web of Science ®Google Scholar
• LASSMANN H, BRUCK W, LUCCHINETTI C, RODRIGUEZ M: Remyelination in multiple sclerosis. Multiple Sclero-sis (1997) 3(2):133–136.
   PubMed Web of Science ®Google Scholar
• BRUCK W, SCHMIED M, SUCHANEK G et al.: Oligoden-drocytes in the early course of multiple sclerosis. Ann. Neurol. (1994) 35(1):65–73.
   PubMedGoogle Scholar
• OZAWA K, SUCHANEK G, BREITSCHOPF H et al.: Patterns of oligodendroglia pathology in multiple sclerosis. Brain (1994) 117(Pt 6) :1311–1322.
   PubMedGoogle Scholar
• PRINEAS JW, KWON EE, GOLDENBERG PZ et al.: Multiple sclerosis. Oligodendrocyte proliferation and differen-tiation in fresh lesions. Lab. Invest. (1989) 61 (5) 489–503.
   PubMed Web of Science ®Google Scholar
• BONETTI B, RAINE CS: Multiple sclerosis: oligodendro-cytes display cell death-related molecules in situ but do not undergo apoptosis. Ann. Neurol. (1997) 42 (1) :74–84.
   PubMed Web of Science ®Google Scholar
• VAN ANTWERP DJ, MARTIN SJ, KAFRI T, GREEN DR, VERMA IM: Suppression of TNF-alpha-induced apopto-sis by NF-kappaB. Science (1996) 274 (5288) :787–789.
   PubMed Web of Science ®Google Scholar
• BEG AA, BALTIMORE D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (1996) 274 (5288) 782–784.
   PubMed Web of Science ®Google Scholar
• GOGATE N, VERMA L, ZHOU JM et al.: Plasticity in the adult human oligodendrocyte lineage. J. Neurosci. (1994) 14 (8) :4571–4587.
   PubMed Web of Science ®Google Scholar
• SCOLDING NJ, RAYNER PJ, SUSSMAN J, SHAW C, COMP-STON DA: A proliferative adult human oligodendro-cyte progenitor. Neuroreport (1995) 6(3) :441–445.
   PubMed Web of Science ®Google Scholar
• WOLSWIJK G: Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligoden-drocyte precursor cells. J. Neurosci. (1998) 18 (2) 601–609.
   PubMed Web of Science ®Google Scholar
• ••This paper describes the evidence for oligodendrocyte pre-cursor cells isolated from adult human MS lesions.
   Google Scholar
• RAFF MC, LILLIEN LE, RICHARDSON WD, BURNE JF, NO-BEL M: Plateletderived growth factor from astrocytes drives the clock that times oligodendrocyte develop-ment in culture. Nature (1988) 333:562–565.
   PubMed Web of Science ®Google Scholar
• LUDWIN SK, SZUCHET S: Myelination by mature ovine oligodendrocytes in vivo and in vitro: evidence that different steps in the myelination process are inde-pendently controlled. Glia (1993) 8:219–231.
   PubMed Web of Science ®Google Scholar
• GARD AL, PFEIFFER SE: Two proliferative stages of the oligodendrocyte lineage (A2B5+04±Galc-) under differ-ent mitogenic control. Neuron (1990) 5:615–625.
   PubMed Web of Science ®Google Scholar
• MCKINNON RD, SMITH C, BEHAR T, SMITH T, DUBOIS-DALCQ M: Distinct effects of bFGF and PDGF on oliog-dendrocyte progenitor cells. Glia (1993) 7:245–254.
   PubMed Web of Science ®Google Scholar
• ROSENBLUTH J, LIU A, GUO D, SCHIFF R: Myelin forma-tion by mouse glia in myelin-deficient rats treated with cyclosporine. j Neurocytol. (1993) 22:967–977.
   PubMedGoogle Scholar
• SANTAMBROGIO L, HOCHWALD GM, SAXENA B et al.: Studies on the mechanisms by which transforming growth factor-beta (TGF- beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor. J. Immunol. (1993) 151(2):1116–1127.
   Google Scholar
• FABRY Z, TOPHAM DJ, FEE D et al: TGF-beta 2 decreases migration of lymphocytes in vitro and homing of cells into the central nervous system in vivo. J. Immunol. (1995) 155(1):325–332.
   PubMed Web of Science ®Google Scholar
• RACKE MK, SRIRAM S, CARLINO J, CANNELLA B, RAINE CS, MCFARLIN DE: Long-term treatment of chronic relaps-ing experimental allergic encephalomyelitis by trans-forming growth factor-beta 2. J. Neuroimmunol. (1993) 46(1-2) :175–183.
   PubMed Web of Science ®Google Scholar
• LIU X, YAO DL, WEBSTER H: Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune en-cephalomyelitis. Multiple Sclerosis (1995) 1 (1) 2–9.
   PubMedGoogle Scholar
• LOVETT-RACKE AE, BITTNER P, CROSS AH, CARLINO JA, RACKE MK: Regulation of experimental autoimmune encephalomyelitis with insulin- like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF- 1/IGFBP3). j Clin. Invest. (1998) 101 (8) :1797–1804.
   PubMed Web of Science ®Google Scholar
• HOBAN CJ: The Neuregulin, GGF2, diminishes autoim-mune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. In: Mul-tiple Sclerosis: Continued Drug Discover)/ and Comprehen-sive Clinical Trials Update. International Business Communications, Cambridge, MA (1997).
   Google Scholar
• MILNER R: Understanding the molecular basis of cell migration; implications for clinical therapy in multi-ple sclerosis. Clin. Sci. (1997) 92(2):113–122.
   Web of Science ®Google Scholar
• HUNTER SF, MILLER DJ, RODRIGUEZ M: Monoclonal remyelination-promoting natural autoantibody SCH 94.03: pharmacokinetics and in vivo targets within de-myelinated spinal cord in a mouse model of multiple sclerosis. J. Neurol. Sci. (1997) 150 (2) :103–113.
   Google Scholar
• AGRESTI C, D'URSO D, LEVI G: Reversible inhibitory ef-fects of interferon-gamma and tumour necrosis factor-alpha on oligodendroglial lineage cell prolifera-tion and differentiation in vitro. Eur J Neurosci (1996) 8(6):1106–16.
   PubMed Web of Science ®Google Scholar
• VARTANIAN T, LI Y, ZHAO M, STEFANSSON K: Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med (1995) 1(7)732–43.
   Google Scholar
• BEVER CT, JR., YOUNG D, ANDERSON PA et al.: The ef-fects of 4-aminopyridine in multiple sclerosis pa-tients: results of a randomised, placebo-controlled, double-blind, concentration- controlled, crossover trial. Neurology (1994) 44 (6) :1054–1059.
   Google Scholar
• KOCSIS JD, BOWE CM, WAXMAN SG: Different effects of 4-aminopyridine on sensory and motor fibres: patho-genesis of paresthesias. Neurology (1986) 36 (1) : 117–120.
   PubMed Web of Science ®Google Scholar
• SCHWID SR, PETRIE MD, MCDERMOTT MP, TIERNEY DS, MASON DH, GOODMAN AD Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology (1997) 48(4):817–821.
   PubMed Web of Science ®Google Scholar